tag:blogger.com,1999:blog-6173393362223742012.post9202444680869284652..comments2023-08-24T08:30:25.608-07:00Comments on Gene Sherpas: Personalized Medicine and You: 2011 Comes to a close. What we know about Personalized MedicineSteve Murphy MDhttp://www.blogger.com/profile/11774190000307343476noreply@blogger.comBlogger3125tag:blogger.com,1999:blog-6173393362223742012.post-91038485994635741602012-03-01T18:07:29.146-08:002012-03-01T18:07:29.146-08:00I think that if we can ascertain quality and peer ...I think that if we can ascertain quality and peer collaboration, it is an excellent idea.Steven Murphy MDhttps://www.blogger.com/profile/14591520761803672451noreply@blogger.comtag:blogger.com,1999:blog-6173393362223742012.post-73770007513584739942012-03-01T11:17:38.769-08:002012-03-01T11:17:38.769-08:00How do you feel about companies that provide simil...How do you feel about companies that provide similar personalized genetics services but bundled into more traditional medical practice models, in more of a "full-service direct-to-consumer personalized genetic bundle" rather than simply the DTC testing (such as Existence Health/Existence Genetics)?Medicalgeneticsserviceshttps://www.blogger.com/profile/09896296055279716424noreply@blogger.comtag:blogger.com,1999:blog-6173393362223742012.post-88693588107053540572012-01-03T20:01:50.591-08:002012-01-03T20:01:50.591-08:00The future of personalized medicine will likely re...The future of personalized medicine will likely require a complete recalibration of our notion of PGx. A brilliant new article on the effect of KIF6 on vulnerability to LDL cholesterol in PLoS ONE suggests that instead of using SNPs to predict pharmacologic response to a particular medication, we should focus on using SNPs to predict expected clinical benefit of a treatment by predicting our vulnerability to LDL, BP and other modifiable risk factors for CVD.Trumannoreply@blogger.com